Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)
Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.
In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.
It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.
This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Wan-Chuan Tsai, M.D., Ph.D.
- Puhelinnumero: 1780 886-289667000
- Sähköposti: mkks618@gmail.com
Opiskelupaikat
-
-
Banciao Dist.
-
New Taipei City, Banciao Dist., Taiwan, 220
- Far Eastern Memorial Hospital
-
Ottaa yhteyttä:
- Wan-Chuan Tsai, M.D., Ph.D.
- Puhelinnumero: 1780 886-277281780
- Sähköposti: mkks618@gmail.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Diagnosis of Restless Legs Syndrome according to standard criteria.
- Age ≥ 20 years.
- Maintenance high-flux hemodialysis for ≥ 3 months.
- Stable vascular access (AV fistula or AV graft).
- Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
- Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
- Clinically stable condition for the past 4 weeks.
- Able and willing to comply with study protocol
Exclusion Criteria:
- Low-flux HD or temporary catheter use
- Serum albumin < 2.5 g/dL
- Recent hospitalization (within 4 weeks)
- Scheduled kidney transplantation
- Active malignancy or infection
- Pregnancy
- Any condition impairing protocol adherence
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Yksittäinen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
|
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
|
|
Ei väliintuloa: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit.
The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from Baseline in International Restless Legs Scale (IRLS) Score
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity).
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Albumin Level
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses sleep quality.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in 5-D Itch Scale Score
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses pruritus severity.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses quality of life.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Kappa Free Light Chains Reduction ratio
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Lambda Free Light Chains Reduction ratio
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Aikaikkuna: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Hermoston sairaudet
- Mielenterveyshäiriöt
- Patologiset prosessit
- Miesten urogenitaaliset sairaudet
- Munuaissairaudet
- Urologiset sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Krooninen sairaus
- Sairauden ominaisuudet
- Uniherätyshäiriöt
- Munuaisten vajaatoiminta
- Unihäiriöt, luontaiset
- Dyssomniat
- Parasomniat
- Patologiset tilat, merkit ja oireet
- Munuaisten vajaatoiminta, krooninen
- Munuaisten vajaatoiminta, krooninen
- Levottomien jalkojen syndrooma
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- FEMH-IRB-TSAI2025
- FEMH-IIT-2026-01 (Muu apuraha/rahoitusnumero: Far Eastern Memorial Hospital)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
IPD-jaon aikakehys
IPD-jaon käyttöoikeuskriteerit
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .